Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Saturday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners started coverage on Lipocine in a research report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price objective on the stock.

Lipocine Stock Performance

Shares of LPCN opened at $4.30 on Friday. The firm has a market cap of $23.01 million, a P/E ratio of -5.66 and a beta of 1.18. Lipocine has a 52 week low of $2.40 and a 52 week high of $11.79. The firm’s 50-day simple moving average is $5.07 and its 200 day simple moving average is $5.61.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. As a group, equities analysts forecast that Lipocine will post -0.78 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lipocine stock. Renaissance Technologies LLC increased its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 21.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,697 shares of the specialty pharmaceutical company’s stock after buying an additional 4,600 shares during the quarter. Renaissance Technologies LLC owned about 0.48% of Lipocine worth $212,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.